Stock AnalizChemed Corp. CHE
Medical/Nursing Services · data as of November 13, 2026
Chemed Corp. (CHE) is a healthcare company listed in the US with a market value of about $7.1B. In the twelve months to September 30, 2026 it had revenue of $2.7B and net income of $282M, a net margin of 10.6%.
Its overall Stock Analiz score is 2.4 out of 5 (weak). The strongest part is financial health (5/5); the weakest is value (0/5).
Key numbers: a P/E of 26.3, a price to free cash flow of 24.1, 5-year revenue growth of 4% a year, a 5-year average ROIC of 24%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 8% below the current price.
Score: 2.4 / 5
Checks passed
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- ROE above 15%
- More cash than debt, or low debt to equity
- Positive free cash flow
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.7B | $2.5B | $2.4B | $2.3B | $2.1B | $2.1B | $2.1B | $1.9B | $1.8B | $1.7B | $1.6B |
| Net income | $282M | $265M | $302M | $273M | $250M | $269M | $319M | $220M | $206M | $98M | $109M |
| Free cash flow | $295M | $325M | $368M | $273M | $253M | $250M | $430M | $248M | $234M | $98M | $96M |
| EPS (diluted) | $20.87 | $18.34 | $19.89 | $17.93 | $16.53 | $16.85 | $19.48 | $13.31 | $12.23 | $5.86 | $6.48 |
| Net margin | 10.6% | 10.5% | 12.4% | 12.0% | 11.7% | 12.6% | 15.4% | 11.3% | 11.5% | 5.9% | 6.9% |
| ROIC | — | 22.4% | 22.0% | 21.2% | 24.9% | 27.8% | 30.3% | 23.0% | 30.7% | 14.8% | 17.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $617.00, 13% above the current price; targets range from $580.00 to $675.00; the consensus rating is “none”; expected EPS is $25.78 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Chemed’s P/E ratio?
About 26.3, based on the last twelve months of diluted earnings per share (forward P/E about 20.0).
Is Chemed stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 8% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Chemed pay a dividend?
Yes. The dividend yield is about 0.51%, and it has paid dividends for 10 years in our data.
Is Chemed a good stock to buy?
We do not give buy or sell advice. Chemed scores 2.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.